Effect of aspirin and aspirin lysinate on platelet function in smokers and non-smokers.
When administered orally, both acetylsalicylic acid and acetylsalicylic acid lysinate produced an increased bleeding time, reduced platelet adhesiveness and inhibition of the second phase of ADP-induced platelet aggregation in the majority of subjects. The effects on bleeding time and adhesiveness were similar for both drugs. Platelet aggregation studies demonstrated slight differences between smokers and non-smokers, in both control samples and in response to the two drugs. It is concluded that aspirin lysinate should provide a good candidate for clinical investigation, to assess its value in the treatment of thrombotic disease.
D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors; D000328:Adult; D001241:Aspirin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D001760:Bleeding Time; D001792:Blood Platelets / Q000502:physiology*; D006801:Humans; D008239:Lysine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D012907:Smoking / Q000503:physiopathology*; D013927:Thrombosis / Q000188:drug therapy
D000244:Adenosine Diphosphate; D008239:Lysine; D001241:Aspirin; C010395:acetylsalicylic acid lysinate